The BridgeTech Program, run and administered by QUT, is holding its second seminar for the year in Melbourne at the Bio21 Institute.
The program trains participants on the complex parts of the commercialisation process for medical technology and medical devices and will share this seminar with its inaugural cohort who were selected earlier in the year.
Speakers for the seminar include industry leaders:
– Jenny Petering, Of Counsel, FB Rice
– Bronwyn Le Grice, Managing Director, ANDHealth.
Bringing expertise in the area of IP and patent strategy in the Australian Biotechnology space, Ms Petering shares
her sector knowledge with participants and also touches on her experience with early stage funding opportunities
and mentoring.
Complementing this talk, Ms Le Grice draws on her 15 years of executive experience in health technology with a current focus on the digital health space, which is at the forefront of this exciting sector.
The BridgeTech Program includes online training modules, an occasional speaker series and a 3-day training workshop that will strengthen the new skills and networks created throughout the program.
Specifically, The BridgeTech Program aims to train researchers and entrepreneurs on the scientific, legal, financial, clinical, regulatory and reimbursement disciplines related to taking new medical technology to market.
The program is convened and administered by QUT and involves a consortium of partners who provide input, advice and networks to this innovative initiative.
Comprising Australian medtech companies, universities and industry associations, The BridgeTech Program consortium has 21 partners including:
- The Actuator
- Agilent Technologies
- AusBiotech
- Australia China Technology Incubator
- Cochlear
- Deakin University
- Flinders University
- Gadens
- Hydrix
- IDE Group
- Life Sciences Queensland
- Magnetica
- Macquarie University
- MTAA
- Queensland University of Technology
- Siemens Healthcare
- Stryker
- University of Melbourne
- University of New South Wales
- University of Newcastle
- University of Western Australia.
The BridgeTech Program is also supported by MTPConnect – the Medical Technologies and Pharmaceuticals Industry Growth Centre – who are providing industry matched funding to run the program.
The inaugural offering of this program selected 80 participants to take part in this highly selective program with the core goal of equipping Australian researchers and entrepreneurs with the necessary skills and networks needed to take new medtech developments to market.
Professor Lyn Griffiths, Project Director of The BridgeTech Program and Executive Director of the IHBI, QUT, said “developing this important educational initiative in partnership with industry means that participants will be provided with relevant and specific commercialisation training, advice and networks to better assist the commercialisation of medical technology and medical devices in Australia”.
For information on the BridgeTech Program, email bridgetech.program@qut.edu.au.